View:
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Hibben Edward K.

(Last) (First) (Middle)
C/O CATABASIS PHARMACEUTICALS, INC.
ONE KENDALL SQ, BLDG 1400E, STE B14202

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/15/2017
3. Issuer Name and Ticker or Trading Symbol
CATABASIS PHARMACEUTICALS INC [ CATB ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Business Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 04/29/2025 Common Stock 77,042 11.05 D
Stock Option (right to buy) (2) 02/10/2026 Common Stock 30,000 4.57 D
Stock Option (right to buy) (3) 09/07/2026 Common Stock 40,000 4.31 D
Stock Option (right to buy) (4) 02/08/2027 Common Stock 100,000 1.24 D
Explanation of Responses:
1. This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 15, 2015 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
2. This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 11, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
3. This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
4. This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 9, 2017 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
Edward K. Hibben 02/17/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                                                                    Exhibit 24.1

                           LIMITED POWER OF ATTORNEY
                      FOR SECTION 16 REPORTING OBLIGATIONS

      Know all by these presents, that the undersigned hereby makes, constitutes
and  appoints  each  of  Jill  C. Milne, Deirdre A. Cunnane and Andrea Matthews,
signing  singly  and  each  acting  individually,  as the undersigned's true and
lawful  attorney-in-fact  with full power and authority as hereinafter described
to:

      (1)   execute  for  and on behalf of the undersigned, in the undersigned's
            capacity  as  an  officer  of  Catabasis  Pharmaceuticals, Inc. (the
            "Company"),  Forms 3, 4, and 5 (including any amendments thereto) in
            accordance with Section 16(a) of the Securities Exchange Act of 1934
            and the rules thereunder (the "Exchange Act");

      (2)   do and perform any and all acts for and on behalf of the undersigned
            which may be necessary or desirable to prepare, complete and execute
            any  such  Form  3,  4,  or  5,  prepare,  complete  and execute any
            amendment  or  amendments  thereto, and timely deliver and file such
            form  with the United States Securities and Exchange Commission (the
            "SEC")  and  any  stock  exchange  or  similar  authority, including
            without  limitation  the  filing of a Form ID, Update Passphrase, or
            any other application materials to enable the undersigned to gain or
            maintain  access
  to  the  Electronic  Data  Gathering, Analysis and
            Retrieval system of the SEC;

      (3)   seek  or  obtain,  as  the  undersigned's  representative and on the
            undersigned's  behalf,  information  regarding  transactions  in the
            Company's  securities  from  any  third  party,  including  brokers,
            employee   benefit   plan   administrators  and  trustees,  and  the
            undersigned  hereby  authorizes  any such person to release any such
            information  to  such attorney-in-fact and approves and ratifies any
            such release of information; and

      (4)   take  any other action of any type whatsoever in connection with the
            foregoing  which, in the opinion of such attorney-in-fact, may be of
            benefit  to,  in  the  best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by such
            attorney-in-fact on behalf of the undersigned pursuant to this Power
            of  Attorney  shall be in such form and shall contain such terms and
            conditions   as   such   attorney-in-fact   may   approve   in  such
            attorney-in-fact's discretion.

The  undersigned  hereby  grants  to  each  such attorney-in-fact full power and
authority  to  do  and perform any and every act and thing whatsoever requisite,
necessary,  or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could  do  if personally present, with full power of substitution or revocation,
hereby  ratifying  and  confirming  all  that  such  attorney-in-fact,  or  such
attorney-in-fact's  substitute  or substitutes, shall lawfully do or cause to be
done  by  virtue  of  this  power  of  attorney and the rights and powers herein
granted.  The  undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming nor
relieving,  nor  is the Company assuming nor relieving, any of the undersigned's
responsibilities  to comply with Section 16 of the Exchange Act. The undersigned
acknowledges that neither the Company nor the foregoing attorneys-in-fact assume
(i)  any  liability  for  the  undersigned's  responsibility  to comply with the
requirement  of  the Exchange Act, (ii) any liability of the undersigned for any
failure  to  comply with such requirements, or (iii) any obligation or liability
of  the  undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

      This  Power  of  Attorney  shall remain in full force and effect until the
undersigned  is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's  holdings of and transactions in securities issued by the Company,
unless  earlier  revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

      IN  WITNESS  WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of February 15, 2017.

                                               /s/ Edward K. Hibben
                                               ---------------------------------
                                               Edward K. Hibben